Portal de Periódicos da CAPES

Effects of calcitriol and paricalcitol on renal fibrosis in CKD

2020; Oxford University Press; Volume: 36; Issue: 5 Linguagem: Inglês

10.1093/ndt/gfaa373

1460-2385

Laura Martínez‐Arias, Sara Panizo, Cristina Alonso‐Montes, Julia Martín-Vírgala, Beatriz Martín-Carro, Sara Fernández-Villabrille, Carmen García Gil-Albert, Carmen Palomo-Antequera, José Luis Fernández Martín, María Piedad Ruiz‐Torres, Adriana Dusso, Natalia Carrillo‐López, Jorge B. Cannata‐Andía, Manuel Naves‐Díaz,

Electrolyte and hormonal disorders

In chronic kidney disease, the activation of the renin-angiotensin-aldosterone system (RAAS) and renal inflammation stimulates renal fibrosis and the progression to end-stage renal disease. The low levels of vitamin D receptor (VDR) and its activators (VDRAs) contribute to worsen secondary hyperparathyroidism and renal fibrosis.The 7/8 nephrectomy model of experimental chronic renal failure (CRF) was used to examine the anti-fibrotic effects of treatment with two VDRAs, paricalcitol and calcitriol, at equivalent doses (3/1 dose ratio) during 4 weeks.CRF increased the activation of the RAAS, renal inflammation and interstitial fibrosis. Paricalcitol treatment reduced renal collagen I and renal interstitial fibrosis by decreasing the activation of the RAAS through renal changes in renin, angiotensin receptor 1 (ATR1) and ATR2 mRNAs levels and renal inflammation by decreasing renal inflammatory leucocytes (CD45), a desintegrin and metaloproteinase mRNA, transforming growth factor beta mRNA and protein, and maintaining E-cadherin mRNA levels. Calcitriol showed similar trends without significant changes in most of these biomarkers.Paricalcitol effectively attenuated the renal interstitial fibrosis induced by CRF through a combination of inhibitory actions on the RAAS, inflammation and epithelial/mesenchymal transition.